SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Parallax Health Sciences, Inc. – ‘8-K’ for 3/30/20

On:  Monday, 3/30/20, at 5:08pm ET   ·   For:  3/30/20   ·   Accession #:  1388410-20-33   ·   File #:  0-52534

Previous ‘8-K’:  ‘8-K’ on 3/13/20 for 3/5/20   ·   Next:  ‘8-K’ on 4/9/20 for 4/7/20   ·   Latest:  ‘8-K’ on 5/12/22 for 5/11/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/30/20  Parallax Health Sciences, Inc.    8-K:8,9     3/30/20    2:42K

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     23K 
 2: EX-99       Ex 99.1 Statement From Freedman & Goldberg CPAs     HTML      7K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
  Current Report  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 30, 2020

 

PHS-logo-032918 50.jpg 

 

PARALLAX HEALTH SCIENCES, INC.

(Exact name of Company as specified in its charter)

 

Nevada

000-52534

46-4733512

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

 

Identification Number)

 

1327 Ocean Avenue, Suite B

Santa Monica, CA 90401

(Address of principal executive offices)

 

310-899-4442

(Registrant’s Telephone Number)

 

 

Copy of all Communications to:

Peter V. Hogan

Buchalter

1000 Wilshire Boulevard, Suite 1500

Los Angeles, CA 90017

(213) 891-0700

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company

þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

¨



 

 

As used in this current report and unless otherwise indicated, the terms "we", "us", "our", “Company”, and “Parallax” mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.

 

 

ITEM 8.01OTHER EVENTS 

 

Reference is made to the order of the U.S. Securities and Exchange Commission, dated March 25, 2020: Order Under Section 36 of the Securities Exchange Act of 1934 Modifying Exemptions from the Reporting and Proxy Delivery Requirements for Public Companies (Release No. 34-88465) (the “Order”). The Order extends the deadlines for filing certain reports made under the Securities Exchange Act of 1934 (the “Exchange Act”), including annual reports on Form 10-K, for registrants subject to the reporting obligations under the Exchange Act that have been impacted by the novel coronavirus disease, COVID-19, and which reports have filing deadlines between March 1 and July 1, 2020.

 

In accordance with the provisions of the Order, the Company is hereby providing notice of its inability to meet the filing deadline for its Form 10-K Annual Report, due on March 30, 2020, as a result of the impact of the COVID-19 pandemic on its business and operations. As required by the Order:

 

1.The Company is relying on the Order in connection with the filing of its 2019 Annual Report on Form 10-K; 

2.As  a direct result of the COVID-19 pandemic in the United States, the social distancing limitations placed upon the Company’s staff and management, and the reduction in common business-related services, the routine efforts of the Company’s accounting and finance personnel have significantly been affected in connection with the completion of the Company’s financial statements and the work required to complete the 2019 audit.  As a result, the Company is unable to finalize and file its Annual Report on Form 10-K on a timely basis. 

3.The Company estimates that it will file its Annual Report on Form 10-K on or about April 30, 2020

4.As a smaller reporting company, the Company is not required to provide risk factors in its Annual Reports.  However, the Company intends on including the following information within its 2019 Annual Report on Form 10-K: 

In December 2019, an outbreak of the COVID-19 virus was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared the COVID-19 virus a global pandemic, and on March 13, 2020, President Donald J. Trump declared the virus a national emergency in the United States. This highly contagious disease has spread to most of the countries in the world and throughout the United States, creating a serious impact on customers, workforces and suppliers, disrupting economies and financial markets, and potentially leading to a world-wide economic downturn. It has caused a disruption of the normal operations of many businesses, including the temporary closure or scale-back of business operations and/or the imposition of either quarantine or remote work or meeting requirements for employees, either by government order or on a voluntary basis. The pandemic may adversely affect our customers’ operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. These effects, and the direct effect of the virus and the disruption on our employees and operations, may negatively impact both our ability to meet customer demand and our revenue and profit margins. Our employees, in many cases, are working remotely and using various technologies to perform their functions. We might experience delays or changes in customer demand, particularly if customer funding priorities change. Further, in reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. Additionally, the disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.

5.The Company’s independent audit firm, Freedman & Goldberg, CPAs, has also been affected by the COVID-19 pandemic.  Their statement is attached herewith as Exhibit 99.1

 

Forward-Looking Statements

Information included in this Current Report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. The Company's actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. The Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS 

 

(d) Exhibits

 

Exhibit

Number

Description of Exhibit

Filing Reference

99.1

Statement from Freedman & Goldberg, CPAs dated March 30, 2020

Filed herewith



 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

PARALLAX HEALTH SCIENCES, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dated: March 30, 2020

/s/ Paul R. Arena

 

 

 

Paul R. Arena

 

 

 

Chief Executive Officer

 

 

 

 

 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
7/1/20
4/30/20
Filed on / For Period end:3/30/20
3/25/20
3/13/208-K
3/11/208-K
 List all Filings 
Top
Filing Submission 0001388410-20-000033   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:42:53.2pm ET